European Heart Journal - Cardiovascular Pharmacotherapy

SJR Rank #1,434H-index: 50SJR: 2.014Best quartile: Q1APC: US$4,501
Journal website: aims, scope and author guidelines
Publisher

Oxford University Press

Country

United Kingdom

Type

journal

SJR by Edition

2022202500.551.11.652.2

Subject Categories

  • Cardiology and Cardiovascular MedicineQ1
  • Pharmacology (medical)Q1

Areas: Medicine

Most published research topics

Atrial Fibrillation Management and OutcomesAntiplatelet Therapy and Cardiovascular DiseasesAcute Myocardial Infarction ResearchHeart Failure Treatment and ManagementLipoproteins and Cardiovascular HealthDiabetes Treatment and ManagementVenous Thromboembolism Diagnosis and ManagementCoronary Interventions and DiagnosticsCardiac electrophysiology and arrhythmiasBlood Pressure and Hypertension Studies

Source: OpenAlex

Publication Statistics

2025 Docs3-Year DocsCitable Docs080160240320

Documents per Year

202220250306090120

Detailed Information

ISSN

2055-6837, 2055-6845

SJR Best Quartile

Q1

Region

Western Europe

Citations per Document (2 years)

4.32

References per Document

27.46

Coverage

2015-2026

Scope

The European Heart Journal - Cardiovascular Pharmacotherapy (EHJ-CVP) is an international, English language, peer-reviewed journal with a specific focus on clinical cardiovascular pharmacology. It publishes original articles concerning clinical research, with new and established drugs and methods, as well as meta-analysis and topical reviews. The journal aims to improve the pharmacological treatment of patients with cardiovascular disease through interpreting and integrating new scientific developments within this area. While the focus is on clinical topics, basic research articles from fields such as physiology and molecular biology which contribute to an understanding of cardiovascular drug therapy are also considered, such as articles relevant to new drug development and evaluation, physiological and pharmacological bases of drug action, metabolism, drug interactions and side effects.

Metrics from SCImago Journal Rank 2025. View on SCImago